Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data.
Pelzer PT, Stuck L, Martinez L, Richards AS, Acuña-Villaorduña C, Aronson NE, Bonnet M, Carvalho AC, Chan PC, Huang LM, Fang CT, Churchyard G, Corral-Londoño HD, Datta M, Espinal MA, Fielding K, Fiore-Gartland AJ, Garcia-Basteiro A, Hanekom W, Hatherill M, Hill PC, Huerga H, Jones-López EC, Kritski A, Mandalakas AM, Mangtani P, Martins Netto E, Mayanja H, Mazahir R, Murray M, Rangaka M, Scriba T, Singh J, Singh S, Stein CM, Vekemans J, Verhagen LM, Villalba JA, Wajja A, Watson B, White RG, Cobelens FGJ. Pelzer PT, et al. Among authors: wajja a. Lancet Microbe. 2024 Dec 19:100961. doi: 10.1016/j.lanmic.2024.100961. Online ahead of print. Lancet Microbe. 2024. PMID: 39709975 Free article.
Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants.
Lutwama F, Kagina BM, Wajja A, Waiswa F, Mansoor N, Kirimunda S, Hughes EJ, Kiwanuka N, Joloba ML, Musoke P, Scriba TJ, Mayanja-Kizza H, Day CL, Hanekom WA. Lutwama F, et al. Among authors: wajja a. J Infect Dis. 2014 Mar;209(6):887-97. doi: 10.1093/infdis/jit570. Epub 2013 Oct 31. J Infect Dis. 2014. PMID: 24179111 Free PMC article. Clinical Trial.
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Lancet Infect Dis. 2024 Mar;24(3):285-296. doi: 10.1016/S1473-3099(23)00501-7. Epub 2023 Nov 25. Lancet Infect Dis. 2024. PMID: 38012890 Free article. Clinical Trial.
Schistosome and malaria exposure and urban-rural differences in vaccine responses in Uganda: a causal mediation analysis using data from three linked randomised controlled trials.
Natukunda A, Nkurunungi G, Zirimenya L, Nassuuna J, Zziwa C, Ninsiima C, Tumusiime J, Nyanzi R, Namutebi M, Kiwudhu F, van Dam GJ, Corstjens PLAM, Kizindo R, Nkangi R, Kabagenyi J, Nassanga B, Cose S, Wajja A, Kaleebu P, Elliott AM, Webb EL; POPVAC trial team. Natukunda A, et al. Among authors: wajja a. Lancet Glob Health. 2024 Nov;12(11):e1860-e1870. doi: 10.1016/S2214-109X(24)00340-1. Lancet Glob Health. 2024. PMID: 39424574 Free PMC article. Clinical Trial.
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Powell Doherty R, Marshall JL, Cabrera Puig I, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Lancet Infect Dis. 2024 Feb;24(2):e78-e79. doi: 10.1016/S1473-3099(23)00758-2. Epub 2024 Jan 3. Lancet Infect Dis. 2024. PMID: 38184003 No abstract available.
The effect of intensive praziquantel administration on vaccine-specific responses among schoolchildren in Ugandan schistosomiasis-endemic islands (POPVAC A): an open-label, randomised controlled trial.
Nkurunungi G, Nassuuna J, Natukunda A, Zirimenya L, Walusimbi B, Zziwa C, Ninsiima C, Kabagenyi J, Kabuubi PN, van Dam GJ, Corstjens PLAM, Kayiwa J, Kizza M, Mutebe A, Nakazibwe E, Akello FA, Sewankambo M, Kiwanuka S, Cose S, Wajja A, Kaleebu P, Webb EL, Elliott AM; POPVAC trial team. Nkurunungi G, et al. Among authors: wajja a. Lancet Glob Health. 2024 Nov;12(11):e1826-e1837. doi: 10.1016/S2214-109X(24)00280-8. Lancet Glob Health. 2024. PMID: 39424571 Free PMC article. Clinical Trial.
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, Galiwango R, Mutonyi G, Vermaak S, Satti I, Verweij J, Tukahebwa E, Cose S, Levin J, Kaleebu P, Elliott AM, McShane H. Wajja A, et al. PLoS Negl Trop Dis. 2017 May 4;11(5):e0005440. doi: 10.1371/journal.pntd.0005440. eCollection 2017 May. PLoS Negl Trop Dis. 2017. PMID: 28472067 Free PMC article. Clinical Trial.
The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda (POPVAC B): a double-blind, randomised controlled trial.
Zirimenya L, Natukunda A, Nassuuna J, Nkurunungi G, Zziwa C, Ninsiima C, Kukundakwe C, Nankabirwa CM, Katushabe C, Namusobya LK, Oduru G, Kabami G, Kabali J, Kayiwa J, Kabagenyi J, van Dam GJ, Corstjens PLAM, Cose S, Wajja A, Staedke SG, Kaleebu P, Elliott AM, Webb EL; POPVAC trial team. Zirimenya L, et al. Among authors: wajja a. Lancet Glob Health. 2024 Nov;12(11):e1838-e1848. doi: 10.1016/S2214-109X(24)00281-X. Lancet Glob Health. 2024. PMID: 39424572 Free PMC article. Clinical Trial.
32 results